Table of Contents
Leukemia Research and Treatment
Volume 2012, Article ID 101754, 12 pages
http://dx.doi.org/10.1155/2012/101754
Review Article

Clinical Trials and Treatment of ATL

1Department of Hematology, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Nagasaki 852-8523, Japan
2Hematology and Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo 104-0045, Japan

Received 1 August 2011; Accepted 29 September 2011

Academic Editor: Mineki Saito

Copyright © 2012 Kunihiro Tsukasaki and Kensei Tobinai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. Uchiyama, J. Yodoi, and K. Sagawa, “Adult T-cell leukemia: clinical and hematologic features of 16 cases,” Blood, vol. 50, no. 3, pp. 481–492, 1977. View at Google Scholar · View at Scopus
  2. B. J. Poiesz, F. W. Ruscetti, and A. F. Gazdar, “Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 77, no. 12, pp. 7415–7419, 1980. View at Google Scholar · View at Scopus
  3. Y. Hinuma, K. Nagata, and M. Hanaoka, “Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera,” Proceedings of the National Academy of Sciences of the United States of America, vol. 78, no. 10 I, pp. 6476–6480, 1981. View at Google Scholar · View at Scopus
  4. I. Miyoshi, I. Kubonishi, and S. Yoshimoto, “Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells,” Nature, vol. 294, no. 5843, pp. 770–771, 1981. View at Google Scholar · View at Scopus
  5. M. Yoshida, I. Miyoshi, and Y. Hinuma, “Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 6 I, pp. 2031–2035, 1982. View at Google Scholar · View at Scopus
  6. A. Gessain, F. Barin, and J. C. Vernant, “Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis,” The Lancet, vol. 2, no. 8452, pp. 407–410, 1985. View at Google Scholar · View at Scopus
  7. M. Osame, K. Usuku, and S. Izumo, “HTLV-I associated myelopathy, a new clinical entity,” The Lancet, vol. 1, no. 8488, pp. 1031–1032, 1986. View at Google Scholar · View at Scopus
  8. L. LaGrenade, B. Hanchard, V. Fletcher, B. Cranston, and W. Blattner, “Infective dermatitis of Jamaican children: a marker for HTLV-I infection,” The Lancet, vol. 336, no. 8727, pp. 1345–1347, 1990. View at Google Scholar · View at Scopus
  9. M. Mochizuki, T. Watanabe, K. Yamaguchi et al., “HTLV-I uveitis: a distinct clinical entity caused by HTLV-I,” Japanese Journal of Cancer Research, vol. 83, no. 3, pp. 236–239, 1992. View at Google Scholar · View at Scopus
  10. K. Terada, S. Katamine, K. Eguchi et al., “Prevalence of serum and salivary antibodies to HTLV-1 in Sjogren's syndrome,” The Lancet, vol. 344, no. 8930, pp. 1116–1119, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Takatsuki, Adult T-cell Leukemia, Oxford University Press, New York, NY, USA, 1994.
  12. “IARC Working Group on the Evaluation of Carcinogenic Risks to Humans: human immunodeficiency viruses and human T-cell lymphotropic viruses,” in IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, IARC Press, Geneva, Switzerland, 1996.
  13. K. Ohshima, E. S. Jaffe, and M. Kikuchi, “Adult T-cell leukemia/lymphoma,” in WHO Classification of Tumour of Haemaopoietic and Lymphoid Tissues, S. H. Swerdlow, E. Campo, N. L. Harris et al., Eds., pp. 281–284, IARC Press, Lyon, France, 4th edition, 2008. View at Google Scholar
  14. M. Shimoyama, “Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the lymphoma study group (1984-87),” British Journal of Haematology, vol. 79, no. 3, pp. 428–437, 1991. View at Google Scholar · View at Scopus
  15. A. L. Bittencourt, M. D. G. Vieira, C. R. Brites, L. Farre, and H. S. Barbosa, “Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients,” American Journal of Clinical Pathology, vol. 128, no. 5, pp. 875–882, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. M. Amano, M. Kurokawa, K. Ogata, H. Itoh, H. Kataoka, and M. Setoyama, “New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types,” Journal of Dermatology, vol. 35, no. 5, pp. 270–275, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. Y. Sawada, R. Hino, K. Hama et al., “Type of skin eruption is an independent prognostic indicator for adult T-cell leukemia/lymphoma,” Blood, vol. 117, no. 15, pp. 3961–3967, 2011. View at Publisher · View at Google Scholar · View at PubMed
  18. J. M. Bennett, D. Catovsky, M. T. Daniel et al., “Proposals for the classification of chronic (mature) B and T lymphoid leukaemias,” Journal of Clinical Pathology, vol. 42, no. 6, pp. 567–584, 1989. View at Google Scholar
  19. K. Lennert, M. Kikuchi, and E. Sato, “HTLV-positive and -negative T-cell lymphomas. Morphological and immunohistochemical differences between European and HTLV-positive Japanese T-cell lymphomas,” International Journal of Cancer, vol. 35, no. 1, pp. 65–72, 1985. View at Google Scholar · View at Scopus
  20. T. Watanabe, K. Yamaguchi, K. Takatsuki, M. Osame, and M. Yoshida, “Constitutive expression of parathyroid hormone-related protein gene in human T cell leukemia virus type 1 (HTLV-1) carriers and adult T cell leukemia patients that can be trans-activated by HTLV-1 tax gene,” Journal of Experimental Medicine, vol. 172, no. 3, pp. 759–765, 1990. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Nosaka, T. Miyamoto, T. Sakai, H. Mitsuya, T. Suda, and M. Matsuoka, “Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κb ligand on adult T-cell leukemia cells,” Blood, vol. 99, no. 2, pp. 634–640, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Tsuda, T. Sawada, K. M. Sakata, and K. Takatsuki, “Possible mechanisms for the elevation of serum β2-microglobulin levels in adult T-cell leukemia,” International Journal of Hematology, vol. 55, no. 2, pp. 179–187, 1992. View at Google Scholar · View at Scopus
  23. N. Sadamori, S. Ikeda, K. Yamaguchi et al., “Serum deoxythymidine kinase in adult T-cell leukemia-lymphoma and its related disorders,” Leukemia Research, vol. 15, no. 2-3, pp. 99–103, 1991. View at Google Scholar · View at Scopus
  24. S. Kamihira, S. Atogami, H. Sohda, S. Momita, Y. Yamada, and M. Tomonaga, “Significance of soluble interleukin-2 receptor levels for evaluation of the progression of adult T-cell leukemia,” Cancer, vol. 73, no. 11, pp. 2753–2758, 1994. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Kamihira, H. Sohda, T. S. Atogami et al., “Phenotypic diversity and prognosis of adult T-cell leukemia,” Leukemia Research, vol. 16, no. 5, pp. 435–441, 1992. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Inagaki, T. Ishida, T. Ishii et al., “Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high Interleukin-5 and -10 levels are significant unfavorable prognostic factors,” International Journal of Cancer, vol. 118, no. 12, pp. 3054–3061, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. T. Ishida, A. Utsunomiya, S. Iida et al., “Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome,” Clinical Cancer Research, vol. 9, no. 10 I, pp. 3625–3634, 2003. View at Google Scholar · View at Scopus
  28. T. Kohno, Y. Yamada, N. Akamatsu et al., “Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells,” Cancer Science, vol. 96, no. 8, pp. 527–533, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. Y. Furukawa, J. Fujisawa, M. Osame et al., “Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV- 1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP),” Blood, vol. 80, no. 4, pp. 1012–1016, 1992. View at Google Scholar · View at Scopus
  30. S. Ikeda, S. Momita, K. I. Kinoshita et al., “Clinical course of human T-lymphotropic virus type I carriers with molecularly detectable monoclonal proliferation of T lymphocytes: defining a low- and high-risk population,” Blood, vol. 82, no. 7, pp. 2017–2024, 1993. View at Google Scholar · View at Scopus
  31. K. Tsukasaki, O. Hermine, A. Bazarbachi et al., “Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting,” Journal of Clinical Oncology, vol. 27, no. 3, pp. 453–459, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. Shimoyama, “Major prognostic factors of patients with adult T-cell leukemia-lymphoma: a cooperative study,” Leukemia Research, vol. 15, no. 2-3, pp. 81–90, 1991. View at Google Scholar · View at Scopus
  33. Y. Yamada, Y. Hatta, K. Murata et al., “Deletions of p15 and/or p16 genes as a poor-prognosis factor in adult T- cell leukemia,” Journal of Clinical Oncology, vol. 15, no. 5, pp. 1778–1785, 1997. View at Google Scholar · View at Scopus
  34. A. Utsunomiya, T. Ishida, A. Inagaki et al., “Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor,” Leukemia Research, vol. 31, no. 7, pp. 915–920, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. Y. Takasaki, M. Iwanaga, K. Tsukasaki et al., “Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL),” Leukemia Research, vol. 31, no. 6, pp. 751–757, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. N. Ohno, A. Tani, K. Uozumi et al., “Expression of functional lung resistance-related protein predicts poor outcome in adult T-cell leukemia,” Blood, vol. 98, no. 4, pp. 1160–1165, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Tawara, S. J. Hogerzeil, Y. Yamada et al., “Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma,” Cancer Letters, vol. 234, no. 2, pp. 249–255, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. Y. Takasaki, M. Iwanaga, Y. Imaizumi et al., “Long-term study of indolent adult T-cell leukemia-lymphoma,” Blood, vol. 115, no. 22, pp. 4337–4343, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. A. Bazarbachi, Y. Plumelle, J. Carlos Ramos et al., “Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes,” Journal of Clinical Oncology, vol. 28, no. 27, pp. 4177–4183, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. M. Shimoyama, K. Ota, M. Kikuchi et al., “Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M,” Journal of Clinical Oncology, vol. 6, no. 1, pp. 128–141, 1988. View at Google Scholar · View at Scopus
  41. M. Shimoyama, K. Ota, M. Kikuchi et al., “Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia,” Journal of Clinical Oncology, vol. 6, no. 7, pp. 1088–1097, 1988. View at Google Scholar · View at Scopus
  42. K. Tobinai, M. Shimoyama, K. Minato et al., “Japan Clinical Oncology Group phase II trial of second-generation LSG4 protocol in aggressive T- and B-lymphoma: a new predictive model for T- and B-lymphoma,” Proceedings of American Society of Clinical Oncology, vol. 13, p. 378, 1994. View at Google Scholar
  43. K. Tobinai, M. Shimoyama, S. Inoue et al., “Phase I study of YK-176 (2'-deoxycoformycin) in patients with adult T-cell leukemia-lymphoma. The DCF Study Group,” Japanese Journal of Clinical Oncology, vol. 22, no. 3, pp. 164–171, 1992. View at Google Scholar · View at Scopus
  44. K. Tsukasaki, K. Tobinai, M. Shimoyama et al., “Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109),” International Journal of Hematology, vol. 77, no. 2, pp. 164–170, 2003. View at Google Scholar · View at Scopus
  45. Y. Yamada, M. Tomonaga, H. Fukuda et al., “A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303,” British Journal of Haematology, vol. 113, no. 2, pp. 375–382, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. K. Tsukasaki, A. Utsunomiya, H. Fukuda et al., “VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group study JCOG9801,” Journal of Clinical Oncology, vol. 25, no. 34, pp. 5458–5464, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. K. Itoh, T. Ohtsu, H. Fukuda et al., “Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan clinical oncology group study 9505,” Annals of Oncology, vol. 13, no. 9, pp. 1347–1355, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Yasuo, H. Shuichi, F. Tatsuhiko et al., “Expression of P-glycoprotein in adult T-cell leukemia cells,” Blood, vol. 76, no. 10, pp. 2065–2071, 1990. View at Google Scholar
  49. K. Tsukasaki, S. Ikeda, K. Murata et al., “Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia/lymphoma,” Leukemia Research, vol. 17, no. 2, pp. 157–166, 1993. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Ichimaru, S. Kamihira, Y. Moriuchi et al., “Clinical study on the effect of natural α-interferon (HLBI) in the treatment of adult T-cell leukemia,” Gan to Kagaku Ryoho, vol. 15, no. 10, pp. 2975–2981, 1988 (Japanese). View at Google Scholar
  51. P. S. Gill, W. Harrington, M. H. Kaplan et al., “Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine,” The New England Journal of Medicine, vol. 332, no. 26, pp. 1744–1748, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. O. Hermine, D. Bouscary, A. Gessain et al., “Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa,” The New England Journal of Medicine, vol. 332, no. 26, pp. 1749–1751, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. K. Tobinai, Y. Kobayashi, M. Shimoyama et al., “Interferon alfa and zidovudine in adult T-cell leukemia-lymphoma,” The New England Journal of Medicine, vol. 333, no. 19, pp. 1285–1286, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. J. D. White, G. Wharfe, D. M. Stewart et al., “The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia/lymphoma,” Leukemia and Lymphoma, vol. 40, no. 3-4, pp. 287–294, 2001. View at Google Scholar · View at Scopus
  55. E. Matutes, G. P. Taylor, J. Cavenagh et al., “Interferon α and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients,” British Journal of Haematology, vol. 113, no. 3, pp. 779–784, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. O. Hermine, I. Allard, V. Lévy, B. Arnulf, A. Gessain, and A. Bazarbachi, “A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma,” Hematology Journal, vol. 3, no. 6, pp. 276–282, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. A. Bazarbachi, R. Nasr, M. E. El-Sabban et al., “Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia/lymphoma,” Leukemia, vol. 14, no. 4, pp. 716–721, 2000. View at Google Scholar · View at Scopus
  58. A. Datta, M. Bellon, U. Sinha-Datta et al., “Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence,” Blood, vol. 108, no. 3, pp. 1021–1029, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  59. T. Fukushima, Y. Miyazaki, S. Honda et al., “Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma,” Leukemia, vol. 19, no. 5, pp. 829–834, 2005. View at Publisher · View at Google Scholar · View at PubMed
  60. M. Hishizawa, J. Kanda, A. Utsunomiya et al., “Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study,” Blood, vol. 116, no. 8, pp. 1369–1376, 2010. View at Publisher · View at Google Scholar · View at PubMed
  61. J. Okamura, A. Utsunomiya, R. Tanosaki et al., “Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma,” Blood, vol. 105, no. 10, pp. 4143–4145, 2005. View at Publisher · View at Google Scholar · View at PubMed
  62. R. Tanosaki, N. Uike, A. Utsunomiya et al., “Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome,” Biology of Blood and Marrow Transplantation, vol. 14, no. 6, pp. 702–708, 2008. View at Publisher · View at Google Scholar · View at PubMed
  63. H. Tamaki and M. Matsuoka, “Donor-derived T-cell leukemia after bone marrow transplantation,” The New England Journal of Medicine, vol. 354, no. 16, pp. 1758–1759, 2006. View at Publisher · View at Google Scholar · View at PubMed
  64. B. D. Cheson, S. J. Horning, B. Coiffier et al., “Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1244–1253, 1999. View at Google Scholar
  65. B. D. Cheson, J. M. Bennett, M. Grever et al., “National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment,” Blood, vol. 87, no. 12, pp. 4990–4997, 1996. View at Google Scholar
  66. B. D. Cheson, B. Pfistner, M. E. Juweid et al., “Revised response criteria for malignant lymphoma,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 579–586, 2007. View at Publisher · View at Google Scholar · View at PubMed
  67. N. Arima, H. Mizoguchi, S. Shirakawa, M. Tomonaga, K. Takatsuki, and R. Ohno, “Phase I clinical study of SH L573 (fludarabine phosphate) in patients with chronic lymphocytic leukemia and adult T-cell leukemia/lymphoma,” Gan to Kagaku Ryoho, vol. 26, no. 5, pp. 619–629, 1999 (Japanese). View at Google Scholar
  68. K. Tobinai, N. Uike, Y. Saburi et al., “Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma,” International Journal of Hematology, vol. 77, no. 5, pp. 512–517, 2003. View at Google Scholar
  69. M. Duvic, A. Forero-Torres, F. Foss et al., “Long-term treatment of CTCL with the oral PNP inhibitor, forodesine,” in Proceedings of the ASCO Annual Meeting, 2009, abstract no. 8552.
  70. O. A. O'Connor, M. L. Heaney, L. Schwartz et al., “Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies,” Journal of Clinical Oncology, vol. 24, no. 1, pp. 166–173, 2006. View at Publisher · View at Google Scholar · View at PubMed
  71. H. Hasegawa, Y. Yamada, K. Tsukasaki et al., “LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway,” Leukemia, vol. 25, no. 4, pp. 575–578, 2011. View at Publisher · View at Google Scholar · View at PubMed
  72. T. A. Waldmann, “Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma,” Journal of the National Cancer Institute, vol. 81, no. 12, pp. 914–923, 1989. View at Google Scholar
  73. T. A. Waldmann, J. D. White, J. A. Carrasquillo et al., “Radioimmunotherapy of interleukin-2Rα-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac,” Blood, vol. 86, no. 11, pp. 4063–4075, 1995. View at Google Scholar
  74. J. L. Berkowitz, J. E. Janik, D. M. Stewart et al., “Phase II trial of daclizumab in human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL),” Journal of Clinical Oncology, vol. 28, supplement, abstract 8043, p. 7s, 2010. View at Google Scholar
  75. N. H. Dang, B. Pro, F. B. Hagemeister et al., “Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma,” British Journal of Haematology, vol. 136, no. 3, pp. 439–447, 2007. View at Publisher · View at Google Scholar · View at PubMed
  76. F. M. Foss, N. N. Sjak-Shie, A. Goy et al., “Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial,” Journal of Clinical Oncology, vol. 28, supplement, abstract 8045, p. 15s, 2010. View at Google Scholar
  77. G. DiVenuti, R. Nawgiri, and F. Foss, “Denileukin diftitox and hyper-CVAD in the treatment of human T-cell lymphotropic virus 1-associated adult T-cell leukemia/lymphoma,” Clinical Lymphoma, vol. 4, no. 3, pp. 176–178, 2003. View at Google Scholar
  78. S. J. Rodig, J. S. Abramson, G. S. Pinkus et al., “Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H),” Clinical Cancer Research, vol. 12, no. 23, pp. 7174–7179, 2006. View at Publisher · View at Google Scholar · View at PubMed
  79. L. Jiang, C. M. Yuan, J. Hubacheck et al., “Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy,” British Journal of Haematology, vol. 145, no. 2, pp. 173–179, 2009. View at Publisher · View at Google Scholar · View at PubMed
  80. A. Gallamini, F. Zaja, C. Patti et al., “Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial,” Blood, vol. 110, no. 7, pp. 2316–2323, 2007. View at Publisher · View at Google Scholar · View at PubMed
  81. Z. Zhang, M. Zhang, C. K. Goldman, J. V. Ravetch, and T. A. Waldmann, “Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H,” Cancer Research, vol. 63, no. 19, pp. 6453–6457, 2003. View at Google Scholar
  82. A. Mone, S. Puhalla, S. Whitman et al., “Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-α-refractory adult T-cell leukemia,” Blood, vol. 106, no. 10, pp. 3380–3382, 2005. View at Publisher · View at Google Scholar · View at PubMed
  83. F. Ravandi and S. Faderl, “Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin,” Leukemia Research, vol. 30, no. 1, pp. 103–105, 2006. View at Publisher · View at Google Scholar · View at PubMed
  84. D. O'Mahony, J. C. Morris, M. Stetler-Stevenson et al., “EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with t-cell malignancies,” Clinical Cancer Research, vol. 15, no. 7, pp. 2514–2522, 2009. View at Publisher · View at Google Scholar · View at PubMed
  85. R. Niwa, E. Shoji-Hosaka, M. Sakurada et al., “Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma,” Cancer Research, vol. 64, no. 6, pp. 2127–2133, 2004. View at Publisher · View at Google Scholar
  86. K. Yamamoto, A. Utsunomiya, K. Tobinai et al., “Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma,” Journal of Clinical Oncology, vol. 28, no. 9, pp. 1591–1598, 2010. View at Publisher · View at Google Scholar · View at PubMed
  87. T. Ishida, T. Joh, N. Uike et al., “Multicenter phase II study of KW-0761, a defucosylated anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma (ATL),” Blood, vol. 116, abstract 285, p. 128, 2010. View at Google Scholar
  88. J. Lee, C. Suh, H. J. Kang et al., “Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma,” Annals of Oncology, vol. 19, no. 12, pp. 2079–2083, 2008. View at Publisher · View at Google Scholar · View at PubMed
  89. Y. Satou, K. Nosaka, Y. Koya, J. I. Yasunaga, S. Toyokuni, and M. Matsuoka, “Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro,” Leukemia, vol. 18, no. 8, pp. 1357–1363, 2004. View at Publisher · View at Google Scholar · View at PubMed
  90. G. S. Dueck, N. Chua, A. Prasad et al., “Activity of lenalidomide in a phase II trial for T-cell lymphoma:Report on the first 24 cases,” Journal of Clinical Oncology, vol. 27, supplement, abstract 8524, p. 15s, 2009. View at Google Scholar
  91. O. A. O'Connor, S. Horwitz, P. Hamlin et al., “Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4357–4364, 2009. View at Publisher · View at Google Scholar · View at PubMed
  92. O. A. O’Connor, B. Pro, L. Pinter-Brown et al., “PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with replapsed or refractory peripheral T-cell lymphoma,” Blood, vol. 112, p. 261, 2008. View at Google Scholar
  93. A. G. Marneros, M. E. Grossman, D. N. Silvers et al., “Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions,” Blood, vol. 113, no. 25, pp. 6338–6341, 2009. View at Publisher · View at Google Scholar · View at PubMed
  94. M. Iwanaga, S. Chiyoda, E. Kusaba, and S. Kamihira, “Trends in the seroprevalence of HTLV-1 in Japanese blood donors in Nagasaki Prefecture, 2000-2006,” International Journal of Hematology, vol. 90, no. 2, pp. 186–190, 2009. View at Publisher · View at Google Scholar · View at PubMed
  95. M. Iwanaga, T. Watanabe, A. Utsunomiya et al., “Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan,” Blood, vol. 116, no. 8, pp. 1211–1219, 2010. View at Publisher · View at Google Scholar · View at PubMed
  96. J. M. Vose, M. Neumann, and M. E. Harris, “International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes international T-cell lymphoma project,” Journal of Clinical Oncology, vol. 26, no. 25, pp. 4124–4130, 2008. View at Publisher · View at Google Scholar · View at PubMed